Annual Report 2020

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2020 153 The United Laboratories International Holdings Limited Annual Report 2020 46. INFORMATION ABOUT THE STATEMENT OF FINANCIAL POSITION OF THE COMPANY (Continued) (b) Reserves Share premium Retained profits Total RMB’000 RMB’000 RMB’000 At 1 January 2019 2,437,831 1,571,286 4,009,117 Loss and total comprehensive expense for the year – (179,953) (179,953) Dividends recognised as distribution (Note 15) – (98,383) (98,383) Issue of shares upon conversion of convertible bonds (Note 30) 8,323 – 8,323 At 31 December 2019 2,446,154 1,292,950 3,739,104 Loss and total comprehensive expense for the year – (319,584) (319,584) Dividends recognised as distribution (Note 15) – (128,140) (128,140) Issue of shares upon conversion of convertible bonds (Note 30) 1,359,541 – 1,359,541 At 31 December 2020 3,805,695 845,226 4,650,921 47. EVENT AFTER THE REPORTING PERIOD Subsequent to the end of reporting period, RMB144,110,000 of commercial bills receivables had been settled by cash and the Group entered into an agreement with Evergrande Chengdu to extend the maturity date of the commercial bills in relation to the remaining balance of RMB100,000,000 which will be matured on 23 April 2021.